These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

961 related articles for article (PubMed ID: 15590954)

  • 1. Cancer of the ovary.
    Cannistra SA
    N Engl J Med; 2004 Dec; 351(24):2519-29. PubMed ID: 15590954
    [No Abstract]   [Full Text] [Related]  

  • 2. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
    J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
    Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
    J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the risk of ovarian cancer.
    Ebell MH
    Am Fam Physician; 2009 Sep; 80(6):632-4. PubMed ID: 19817330
    [No Abstract]   [Full Text] [Related]  

  • 6. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
    Carden CP; Yap TA; Kaye SB
    Curr Opin Oncol; 2010 Sep; 22(5):473-80. PubMed ID: 20485165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
    Grenader T; Peretz T; Lifchitz M; Shavit L
    Breast; 2005 Aug; 14(4):264-8. PubMed ID: 16085232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the management of women with ovarian cancer.
    Eltabbakh GH
    Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.
    Swisher E
    Curr Womens Health Rep; 2003 Feb; 3(1):27-32. PubMed ID: 12521547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
    Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
    Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy for ovarian cancer: an evidence-based approach.
    Geisler JP; Manahan KJ; Wiemann MC
    Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?
    Kauff ND; Barakat RR
    Gynecol Oncol; 2004 May; 93(2):277-9. PubMed ID: 15099933
    [No Abstract]   [Full Text] [Related]  

  • 14. Early detection of breast and ovarian cancer in families with BRCA mutations.
    Vasen HF; Tesfay E; Boonstra H; Mourits MJ; Rutgers E; Verheyen R; Oosterwijk J; Beex L
    Eur J Cancer; 2005 Mar; 41(4):549-54. PubMed ID: 15737559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study.
    Reedy M; Gallion H; Fowler JM; Kryscio R; Smith SA
    Gynecol Oncol; 2002 May; 85(2):255-9. PubMed ID: 11972384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
    Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
    Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of CA-125 in epithelial ovarian cancer patients during and after chemotherapy.
    Lukácskó I; Hernádi Z; Sápy T; Borsos A
    Acta Chir Hung; 1997; 36(1-4):213-4. PubMed ID: 9408350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choices--and uncertainties--for women with BRCA mutations.
    Couzin J
    Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
    Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
    Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
    Hughes DJ; Ginolhac SM; Coupier I; Corbex M; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Maugard C; Olschwang S; Yannoukakos D; Durocher F; Moisan AM; Simard J; Mazoyer S; Lynch HT; Szabo C; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):265-7. PubMed ID: 15668505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.